GlassScriptPhysician profile
Steven G Eisenberg
NPI 1831162627
$12,131.77
in general payments reported to CMS, 2019-2025
69 companies · $1,237 in 2025
The $1,237 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,536 · 2020: $537 · 2021: $852 · 2022: $1,910 · 2023: $3,628 · 2024: $2,432 · 2025: $1,237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,076 · Education: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,076.37 |
| Education | $220.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,047.30 | 2019-2025 | |
| Celgene Corporation | $1,000.43 | 2019-2024 | Reblozyl, Pomalyst, Opdualag |
| Pfizer INC. | $850.50 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $751.82 | 2019-2025 | Reblozyl, Opdivo, Opdualag |
| Gilead Sciences, INC. | $666.40 | 2019-2025 | Trodelvy |
| Alexion Pharmaceuticals, INC. | $596.73 | 2019-2025 | Ultomiris |
| Pharmacyclics LLC, An Abbvie Company | $537.80 | 2019-2023 | Imbruvica, Epkinly |
| Merck Sharp & Dohme LLC | $377.58 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $347.82 | 2019-2024 | Darzalex, Tecvayli, Talvey |
| Coherus Oncology, INC. | $342.78 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $291.87 | 2019-2025 | Tagrisso, Calquence, Imfinzi |
| Seagen INC. | $290.05 | 2019-2023 | Adcetris, Tivdak |
| Amgen INC. | $286.74 | 2019-2023 | Lumakras, Kyprolis, Blincyto |
| Kite Pharma, INC. | $285.18 | 2020-2025 | Yescarta |
| Array Biopharma INC | $261.63 | 2019-2025 | Mektovi, Braftovi, Lorbrena |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Eisenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.